AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03339648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professional Development Enhancement
Description: Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
Study NCT03339648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Development Enhancement
Description: Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
Study NCT04014153 — intervention group
Intervention type: PROCEDURE
Intervention: Iodinated contrast media
Description: Percutaneous coronary intervention with iodinated contest media
Study NCT06326840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
Study NCT01591018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sonolysis
Description: continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
Study NCT01806727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Lifestyle Weight Loss (LWL)
Description: Changing dietary and physical activity behavior to promote weight loss
Study NCT00564031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gestapuran
Description: 5mg/day
Study NCT00564031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily
Study NCT00564031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femanest plus Gestapuran
Description: combined daily
Study NCT04392596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density and Trabecular Bone score
Description: structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk \[22\]: any TBS >1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS \<1.23 was considered as degraded structure.
Study NCT03513224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eDosette
Description: The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
Study NCT04121507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)
Description: High-dose therapy (HDT) prior to alloSCT will consist of FTC
Study NCT04121507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow histology
Description: Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
Study NCT04121507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinical and laboratory parameters
Description: During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
Study NCT04121507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT or CT
Description: Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
Study NCT02583048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
Study NCT02583048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
Study NCT01806727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management (DSM)
Description: Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
Study NCT00768937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
Study NCT00768937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation (TACE)
Description: TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
Study NCT00894127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPath
Description: CyPath diagnostic assay for the early detection of lung cancer using sputum
Study NCT03176875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALICALM (75% of daily caloric requirements)
Description: PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
Study NCT03176875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALICALM (100% of daily caloric requirements)
Description: EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
Study NCT02240173 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jobelyn
Description: Jobelyn is a dietary supplement made from Sorghum bicolor
Study NCT02240173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Conventional drug normally used for psychotic problems
Study NCT01571297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
Study NCT01571297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given subcutaneously for 35 days
Study NCT03645681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnAVasc arteriovenous graft surgical implant
Description: An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
Study NCT02193425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18FDG
Description: 18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.
Study NCT02193425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Two MRI/MRS sessions to evaluate test-retest reliability of functional connectivity (FC) at rest as well as during task performance.
Study NCT03733340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
Study NCT02819661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOMNOTOUCH RESP
Description: Ventilatory effort recorder
Study NCT02583048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
Study NCT02583048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multidrug Background Treatment (MBT) for TB
Description: A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
Study NCT01090037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP low dose
Study NCT01090037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00670982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given intravenously every 2 weeks
Study NCT01591018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: coronary artery bypass graft (CABG) heart valve replacement
Study NCT01591018 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cardiac surgery
Description: coronary artery bypass graft (CABG) heart valve replacement
Study NCT00909987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
Study NCT00909987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
Study NCT00909987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
Study NCT00909987 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
Study NCT00909987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine during all Radiotherapy period
Description: 825 mg/m2 bid
Study NCT00909987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Description: 4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
Study NCT02269059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7680
Description: MK-7680 10 mg and 100 mg capsules
Study NCT00216021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Study NCT00216021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV, day 1
Study NCT00670982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Given intravenously once a week
Study NCT00670982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given intravenously once a week
Study NCT04060680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation using the Extravascular ICD
Description: VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
Study NCT00736749 — intervention group
Intervention type: PROCEDURE
Intervention: Assessment of Therapy Complications
Description: Complete patient response form and Health Status Update Form
Study NCT00736749 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete patient response form, Health Status Update Form (called the Keep in Touch form), and Quality of Life Questionnaire (PROMIS)
Study NCT06405321 — intervention group
Intervention type: DRUG
Intervention: Conversion or neoadjuvant therapy.
Description: Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
Study NCT04361630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF 2
Description: Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.
Study NCT04473859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 20μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study NCT04473859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 50μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study NCT04473859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 100μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study NCT04473859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 200μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study NCT04473859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study NCT04473859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study NCT01659138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR339658
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study NCT01659138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT05617235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~1. In order to stimulate the facilitation of the diaphragmatic function~2. Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~3. In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively.
Study NCT04328376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG coupled to phonocardiography
Description: A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.~QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography.
Study NCT01093573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative study
Study NCT00791531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate 5mg once daily for 5 consecutive days
Study NCT02453646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexSite HD Patients
Description: Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
Study NCT02886936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFIT Transtibial Prosthesis
Description: Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
Study NCT02886936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFIT Transfemoral Prosthesis
Description: Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
Study NCT03853590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Description: Creation of a small pouch from the stomach and connection of the newly created pouch directly to the small intestine so that swallowed food bypasses most of the stomach and the first section of the small intestine.
Study NCT01156987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.
Study NCT03853590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Description: Placement of a soft silicone ring with an expandable balloon in the center, around the top part of the stomach to create a two-compartment stomach, with a much smaller top part above the band. The subject will eat enough food only to fill the top part of the stomach decreasing caloric consumption.
Study NCT01536353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSAV301
Description: tablet, q.d.
Study NCT01536353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge 10/160
Description: Tablet, q.d.
Study NCT03605186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamomile oral cryotherapy
Description: The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
Study NCT01093573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic study
Description: Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
Study NCT00522041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellegesic
Description: Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
Study NCT00522041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
Study NCT02011451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 95% Pure ECGC capsules 200mg
Description: Theaphenon 95% 95% Pure EGCG
Study NCT02011451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator:
Study NCT01430286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-social intervention based on a web-based psycho-educational program, called Diapason.
Description: This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
Study NCT01430286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation in memory clinic
Description: This group will receive treatment as usual (consultation in memory clinic every 6 months)
Study NCT02763696 — intervention group
Intervention type: OTHER
Intervention: Composition of Viginal flora of Child-Bearing women
Description: Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
Study NCT04715139 — intervention group
Intervention type: DEVICE
Intervention: Products listed in Group/Cohort Description
Description: Depending on approved indication per product
Study NCT03170739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine given during surgery.
Study NCT03440372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study NCT03440372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04489771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Oral administration
Study NCT03605186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral cryotherapy
Description: The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.